CureVac achieved a net profit of €273.2 million in Q3 2025, mainly due to a €370 million settlement gain and a €50 million license amendment payment. While revenue fell drastically year-over-year without a repeat of last year's GSK payment, strategic cost management and restructuring efforts supported profitability.
Q3 2025 revenue was €54.1 million, significantly lower than €493.9 million in Q3 2024 due to last year's one-time GSK payment.
Net income for the quarter totaled €273.2 million, driven by the U.S. settlement and licensing gains.
EPS for the quarter was €1.21, down from €1.51 in Q3 2024.
Cash and cash equivalents remained strong at €416.1 million, supporting operations into 2028.
CureVac expects continued financial stability and operational focus on oncology and mRNA innovation, with the BioNTech merger progressing toward closing.
Analyze how earnings announcements historically affect stock price performance